The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis

Journal of Dermatological Science

Volumn 59, Issue 3, 2010, Pages 153-162

  Asano, Yoshihide ^a   Bujor, Andreea M ^b   Trojanowska, Maria ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Endothelial cells; Fibroblasts; Fli1; Imatinib; Immune cells; Systemic sclerosis

Indexed keywords

BOSENTAN; CLARITHROMYCIN; DASATINIB; ERYTHROMYCIN; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SILDENAFIL; TRANSCRIPTION FACTOR FLI 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOIMMUNE DISEASE; BLOOD VESSEL INJURY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DOWN REGULATION; DRUG TARGETING; ENDOTHELIUM CELL; EOSINOPHILIC LEUKEMIA; EPIGENETICS; FIBROBLAST; FIBROSING ALVEOLITIS; FIBROSIS; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; LOCALIZED SCLERODERMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

ACETYLATION; ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; COLLAGEN TYPE I; DOWN-REGULATION; DRUG THERAPY, COMBINATION; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FIBROBLASTS; GENE EXPRESSION; HEMATOPOIESIS; HUMANS; MACROLIDES; MICE; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEIN C-FLI-1; PYRIMIDINES; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 77956178350     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.06.008     Document Type: Review

References (100)

1. Asano Y., Czuwara J., Trojanowska M. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007, 282:34672-34683.
2. Asano Y., Markiewicz M., Kubo M., Szalai G., Watson D.K., Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009, 29:425-434.
3. Asano Y., Stawski L., Hant F., Highland K., Silver R., Szalai G., et al. Endothelial Fli1 deficiency impairs vascular homeostasis. A role in scleroderma vasculopathy. Am J Pathol 2010, 176:1983-1998.
4. Asano Y., Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol 2009, 29:1882-1894.
5. Kubo M., Czuwara-Ladykowska J., Moussa O., Markiewicz M., Smith E., Silver R.M., et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003, 163:571-581.
6. Mayes M.D., Trojanowska M. Genetic factors in systemic sclerosis. Arthritis Res Ther 2007, 9:S5.
7. Varga J.A., Trojanowska M. Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008, 34:115-143.
8. Wang Y., Fan P.S., Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54:2271-2279.
9. Hollenhorst P.C., Jones D.A., Graves B.J. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 2004, 32:5693-5702.
10. Hsu T., Trojanowska M., Watson D.K. Ets proteins in biological control and cancer. J Cell Biochem 2004, 91:896-903.
11. Ben-David Y., Giddens E.B., Letwin K., Bernstein A. Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1. Genes Dev 1991, 5:908-918.
12. Delattre O., Zucman J., Plougastel B., Desmaze C., Melot T., Peter M., et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992, 359:162-165.
13. Ida K., Kobayashi S., Taki T., Hanada R., Bessho F., Yamamori S., et al. EWS-FLI-1 and EWS-ERG chimeric mRNAs in Ewing's sarcoma and primitive neuroectodermal tumor. Int J Cancer 1995, 63:500-504.
14. Czuwara-Ladykowska J., Shirasaki F., Jackers P., Watson D.K., Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001, 276:20839-20848.
15. Asano Y., Ihn H., Asashima N., Yazawa N., Mimura Y., Jinnin M., et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford) 2005, 44:824-826.
16. Asano Y., Ihn H., Jinnin M., Mimura Y., Tamaki K. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006, 126:1761-1769.
17. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. Arthritis Rheum 2005, 52:1237-1247.
18. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005, 175:7708-7718.
19. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005, 52:2897-2905.
20. Asano Y., Ihn H., Yamane K., Jinnin M., Mimura Y., Tamaki K. Phosphatidylinositol 3-kinase is involved in alpha2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 2004, 172:7123-7135.
21. Asano Y., Ihn H., Yamane K., Jinnin M., Tamaki K. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006, 168:499-510.
22. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004, 113:253-264.
23. Asano Y., Ihn H., Yamane K., Kubo M., Tamaki K. Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts. Am J Pathol 2004, 164:1275-1292.
24. Ihn H., Yamane K., Asano Y., Jinnin M., Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford) 2006, 45:157-165.
25. Ihn H., Yamane K., Kubo M., Tamaki K. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 2001, 44:474-480.
26. Jinnin M., Ihn H., Mimura Y., Asano Y., Tamaki K. Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor beta signaling in scleroderma fibroblasts. Arthritis Rheum 2007, 56:1694-1705.
27. Jinnin M., Ihn H., Mimura Y., Asano Y., Tamaki K. Potential regulatory elements of the constitutive up-regulated alpha2(I) collagen gene in scleroderma dermal fibroblasts. Biochem Biophys Res Commun 2006, 343:904-909.
28. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., Tamaki K. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005, 124:324-330.
29. Jinnin M., Ihn H., Mimura Y., Asano Y., Yamane K., Tamaki K. Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res 2005, 33:3540-3549.
30. LeRoy E.C. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974, 54:880-889.
31. Mimura Y., Ihn H., Jinnin M., Asano Y., Yamane K., Tamaki K. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 2005, 124:886-892.
32. Mimura Y., Ihn H., Jinnin M., Asano Y., Yamane K., Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-beta signaling in cultured scleroderma fibroblasts. Am J Pathol 2005, 166:1451-1463.
33. Nakerakanti S.S., Kapanadze B., Yamasaki M., Markiewicz M., Trojanowska M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006, 281:25259-25269.
34. Inoue Y., Itoh Y., Abe K., Okamoto T., Daitoku H., Fukamizu A., et al. Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 2007, 26:500-508.
35. Itoh S., Ericsson J., Nishikawa J., Heldin C.H., ten Dijke P. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. Nucleic Acids Res 2000, 28:4291-4298.
36. Simonsson M., Kanduri M., Gronroos E., Heldin C.H., Ericsson J. The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. J Biol Chem 2006, 281:39870-39880.
37. Jimenez S.A., Gaidarova S., Saitta B., Sandorfi N., Herrich D.J., Rosenbloom J.C., et al. Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001, 108:1395-1403.
38. Lagares D., Garcia-Fernandez R.A., Jimenez C.L., Magan-Marchal N., Busnadiego O., Lamas S., et al. Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis. Arthritis Rheum 2010, 62:878-889.
39. Rachfal A.W., Brigstock D.R. Structural and functional properties of CCN proteins. Vitam Horm 2005, 70:69-103.
40. Mori T., Kawara S., Shinozaki M., Hayashi N., Kakinuma T., Igarashi A., et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 1999, 181:153-159.
41. Igarashi A., Nashiro K., Kikuchi K., Sato S., Ihn H., Grotendorst G.R., et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995, 105:280-284.
42. Pannu J., Asano Y., Nakerakanti S., Smith E., Jablonska S., Blaszczyk M., et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008, 58:2528-2537.
43. Hart A., Melet F., Grossfeld P., Chien K., Jones C., Tunnacliffe A., et al. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000, 13:167-177.
44. Spyropoulos D.D., Pharr P.N., Lavenburg K.R., Jackers P., Papas T.S., Ogawa M., et al. Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 2000, 20:5643-5652.
45. Braun-Falco O., Rupec M. Collagen fibrils of the scleroderma in ultra-thin skin sections. Nature 1964, 202:708-709.
46. Fleischmajer R., Damiano V., Nedwich A. Alteration of subcutaneous tissue in systemic scleroderma. Arch Dermatol 1972, 105:59-66.
47. Fleischmajer R., Gay S., Meigel W.N., Perlish J.S. Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 1978, 21:418-428.
48. Sakakibara N., Sugano S., Morita A. Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet A therapy in systemic sclerosis. J Dermatol 2008, 35:63-69.
49. Liu F., Walmsley M., Rodaway A., Patient R. Fli1 acts at the top of the transcriptional network driving blood and endothelial development. Curr Biol 2008, 18:1234-1240.
50. Armulik A., Abramsson A., Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005, 97:512-523.
51. Montagnana M., Volpe A., Lippi G., Caramaschi P., Salvagno G.L., Biasi D., et al. Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis. Clin Biochem 2007, 40:837-842.
52. Allanore Y., Seror R., Chevrot A., Kahan A., Drape J.L. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum 2007, 56:2747-2754.
53. Wang J., Yarnykh V.L., Molitor J.A., Nash R.A., Chu B., Wilson G.J., et al. Micro magnetic resonance angiography of the finger in systemic sclerosis. Rheumatology (Oxford) 2008, 47:1239-1243.
54. Breton-Gorius J., Favier R., Guichard J., Cherif D., Berger R., Debili N., et al. A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23. Blood 1995, 85:1805-1814.
55. Penny L.A., Dell'Aquila M., Jones M.C., Bergoffen J., Cunniff C., Fryns J.P., et al. Clinical and molecular characterization of patients with distal 11q deletions. Am J Hum Genet 1995, 56:676-683.
56. Tunnacliffe A., Jones C., Le Paslier D., Todd R., Cherif D., Birdsall M., et al. Localization of Jacobsen syndrome breakpoints on a 40-Mb physical map of distal chromosome 11q. Genome Res 1999, 9:44-52.
57. Masuya M., Moussa O., Abe T., Deguchi T., Higuchi T., Ebihara Y., et al. Dysregulation of granulocyte, erythrocyte, and NK cell lineages in Fli-1 gene-targeted mice. Blood 2005, 105:95-102.
58. Zhang L., Eddy A., Teng Y.T., Fritzler M., Kluppel M., Melet F., et al. An immunological renal disease in transgenic mice that overexpress Fli-1, a member of the ets family of transcription factor genes. Mol Cell Biol 1995, 15:6961-6970.
59. Mao X., Miesfeldt S., Yang H., Leiden J.M., Thompson C.B. The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 1994, 269:18216-18222.
60. Zhang X.K., Watson D.K. The FLI-1 transcription factor is a short-lived phosphoprotein in T cells. J Biochem 2005, 137:297-302.
61. Bradshaw S., Zheng W.J., Tsoi L.C., Gilkeson G., Zhang X.K. A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis. Clin Immunol 2008, 129:19-30.
62. Zhang X.K., Gallant S., Molano I., Moussa O.M., Ruiz P., Spyropoulos D.D., et al. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J Immunol 2004, 173:6481-6489.
63. Zhang X.K., Moussa O., LaRue A., Bradshaw S., Molano I., Spyropoulos D.D., et al. The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. J Immunol 2008, 181:1644-1654.
64. Sarrazin S., Bonod-Bidaud C., Remy P., Mehlen P., Morle F. Caspase cleavage of the transcription factor FLI-1 during preB leukemic cell death. Biochim Biophys Acta 2002, 1592:123-127.
65. Markiewicz M., Asano Y., Znoyko S., Gong Y., Watson D.K., Trojanowska M. Distinct effects of gonadectomy in male and female mice on collagen fibrillogenesis in the skin. J Dermatol Sci 2007, 47:217-226.
66. Ceni E., Crabb D.W., Foschi M., Mello T., Tarocchi M., Patussi V., et al. Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology 2006, 131:1235-1252.
67. Lasfer M., Davenne L., Vadrot N., Alexia C., Sadji-Ouatas Z., Bringuier A.F., et al. Protein kinase PKC delta and c-Abl are required for mitochondrial apoptosis induction by genotoxic stress in the absence of p53, p73 and Fas receptor. FEBS Lett 2006, 580:2547-2552.
68. Kaur S., Parmar S., Smith J., Katsoulidis E., Li Y., Sassano A., et al. Role of protein kinase C-delta (PKC-delta) in the generation of the effects of IFN-alpha in chronic myelogenous leukemia cells. Exp Hematol 2005, 33:550-1557.
69. Li B., Wang X., Rasheed N., Hu Y., Boast S., Ishii T., et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev 2004, 18:1824-1837.
70. Kin Y., Shibuya M., Maru Y. Inhibition of protein kinase C delta has negative effect on anchorage-independent growth of BCR-ABL-transformed Rat1 cells. Leuk Res 2001, 25:821-825.
71. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
72. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322.
73. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. Faseb J 2005, 19:1-11.
74. Cortes J., Kantarjian H. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer 2004, 100:2064-2078.
75. Handolias D., McArthur G.A. Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer. Future Oncol 2008, 4:211-217.
76. Orfao A., Garcia-Montero A.C., Sanchez L., Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007, 138:12-30.
77. Ravandi F., Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009, 23:1043-1063.
78. Tefferi A., Gotlib J., Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010, 85:158-164.
79. Waller C.F. Imatinib mesylate. Recent Results Cancer Res 2010, 184:3-20.
80. Bhattacharyya S., Ishida W., Wu M., Wilkes M., Mori Y., Hinchcliff M., et al. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28:1285-1297.
81. Kay J., High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008, 58:2543-2548.
82. Magro L., Catteau B., Coiteux V., Bruno B., Jouet J.P., Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008, 42:757-760.
83. Moreno-Romero J.A., Fernandez-Aviles F., Carreras E., Rovira M., Martinez C., Mascaro J.M. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol 2008, 144:1106-1109.
84. Sabnani I., Zucker M.J., Rosenstein E.D., Baran D.A., Arroyo L.H., Tsang P., et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009, 48:49-52.
85. Sfikakis P.P., Gorgoulis V.G., Katsiari C.G., Evangelou K., Kostopoulos C., Black C.M. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008, 47:735-737.
86. van Daele P.L., Dik W.A., Thio H.B., van Hal P.T., van Laar J.A., Hooijkaas H., et al. Is imatinib mesylate a promising drug in systemic sclerosis?. Arthritis Rheum 2008, 58:2549-2552.
87. Ghofrani H.A., Seeger W., Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353:1412-1413.
88. Patterson K.C., Weissmann A., Ahmadi T., Farber H.W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006, 145:152-153.
89. Perros F., Montani D., Dorfmuller P., Durand-Gasselin I., Tcherakian C., Le Pavec J., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 178:81-88.
90. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
91. ten Freyhaus H., Dumitrescu D., Bovenschulte H., Erdmann E., Rosenkranz S. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009, 98:265-267.
92. ClinicalTrials.gov: [] (accessed 27 January 2009). ctgov:http://clinicaltrials.gov/ct2/show/NCT00764309.
93. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
94. Kantarjian H., Jabbour E., Grimley J., Kirkpatrick P., Dasatinib Nat Rev Drug Discov 2006, 5:717-718.
95. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
96. Akhmetshina A., Dees C., Pileckyte M., Maurer B., Axmann R., Jungel A., et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. Faseb J 2008, 22:2214-2222.
97. Varga J., Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200-206.
98. Azuma M., Nishioka Y., Aono Y., Inayama M., Makino H., Kishi J., et al. Role of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 2007, 176:1243-1250.
99. Kucharz E.J., Grucka-Mamczar E., Mamczar A., Brzezinska-Wcislo L. Acute-phase proteins in patients with systemic sclerosis. Clin Rheumatol 2000, 19:165-166.
100. Agarwal S.K., Reveille J.D. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010, 22:133-138.